Summary
Adult Tâcell leukaemiaâlymphoma (ATLL) is an aggressive malignancy of CD4+ CD25+ T lymphocytes, characterized by a severely compromised immunosystem, in which the human Tâcell lymphotropic virus type 1 (HTLVâ1) has been recognized as the aetiological agent. This study found that an IÎșB kinase ÎČ (IKKÎČ) inhibitor Bay11â7082 inactivated mammalian target of rapamycin (mTOR), signal transducer and activator of transcription 3 and transcription factor nuclear factorâÎșB in HTLVâ1âinfected T cells; this was significantly enhanced in the presence of the mTOR inhibitor everolimus. In addition, Bay11â7082 decreased production of the immunosuppressive cytokine interleukinâ10 (ILâ10), which was further downâregulated when Bay11â7082 was combined with evelolimus in HTLVâ1âinfected T and ATLL cells isolated from patients. Interleukinâ10 is known to inhibit maturation and the antigenâpresenting function of dendritic cells (DCs). The culture media of HTLVâ1âinfected MTâ1 cells, which contained a large amout of ILâ10, hampered tumour necrosis factorâαâinduced maturation of DCs isolated from healthy volunteers. Culture supernatant of MTâ1 cells treated with a combination of Bay11â7082 and everolimus augmented maturation of DCs in association with a decrease in production of ILâ10 and enhanced the allostimulatory function of DCs. Similarly, when DCs isolated from patients with ATLL were treated with the combination of Bay11â7082 and everolimus, they were fully matured and their capability to stimulate proliferation of lymphocytes was augmented. Taken together, the combination of Bay11â7082 and everolimus might exhibit immunostimulatory properties in HTLVâ1âinfected T and ATLL cells isolated from patients, and this combination may be potentially therapeutic to regain the compromised immunosystem in ATLL patients.